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Abstract 
Background: An increasing number of studies have demonstrated that deregulation of microRNAs (miRNAs) was 
a common event in tumor tissues and miRNAs would be treated as ideal tumor biomarkers or therapeutic targets. 
miR-195-5p (termed as miR-195 for briefly in the following part) was suggested to function as a tumor suppressor in 
cancer development and progression. However, the roles of miR-195 in human prostate cancer are still elusive. Thus, 
this study was performed to investigate the biological functions and its molecular mechanisms of miR-195 in human 
prostate cancer cell lines, discussing whether it has a potential to be a therapeutic way of prostate cancer.
Methods: Two human prostate cancer cell lines were analyzed for the expression of miR-195 by quantitative real-
time reverse transcription–polymerase chain reaction (RT–PCR). A gain-of-function study of miR-195 was conducted 
by transfecting mimics into DU145 and PC3 cells and cell motility and invasion ability were evaluated by wound 
healing assay and transwell assay. Tissue microarray, and immunohistochemistry with antibodies against Fra-1 was 
performed using the peroxidase and DAB methods. The target gene of miR-195 was determined by luciferase assay, 
quantitative RT–PCR and western blot. The regulation of motility by miR-195 was analyzed by western blot.
Results: miR-195 was frequently down-regulated in both prostate cancer cell lines, DU145 and PC3. Overexpres-
sion of miR-195 significantly repressed the capability of migration and invasion of prostate cancer cells. In addition, 
we identified Fra-1, a cell motility regulator, as a novel target of miR-195. Fra-1 was up-regulated in prostate cancer 
tissues. We also observed that inhibition of miR-195 or restoration of Fra-1 in miR-195-over-expressed prostate cancer 
cells partially reversed the suppressive effects of miR-195. Furthermore, we demonstrated miR-195 could inhibit pros-
tate cancer cell motility by regulated the expression of c-Met, MMP1, MMP9.
Conclusions: miR-195 can repress the migration and invasion of prostate cancer cells via regulating Fra-1. Our results 
indicate that miR-195 could be a tumor suppressor and may have a potential to be a diagnostics or therapeutic target 
in prostate cancer.
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Background
Prostate cancer is the most frequently diagnosed male 
cancer and the second-leading cause of oncological 
mortality in men living in the United States [1]. It is a 
clinically heterogeneous, multifactorial disease and the 
incidence is continuously rising. Like many other solid 
tumors, prostate cancer mortality attributes largely to 
cancer metastasis, a complicated process that involves 
changes in the extracellular matrix to support invasion, 
increased cell motility and the ability of cells to initi-
ate and maintain growth at a distant site [2]. However, 
unlike a majority of solid cancers, prostate cancer usually 
shows poor response to chemotherapy. Therefore, more 
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effective strategies for the targeted treatment of pros-
tate cancer, especially for cancer metastasis, are urgently 
needed.
Carcinogenesis and progression are multistep pro-
cesses, involving numerous genetic mutations, aberrant 
gene expression, and microRNA (miRNA) dysregula-
tion [3]. MicroRNAs (miRNAs), which are widespread in 
eukaryotic cells, are endogenous single stranded, non-
protein-coding RNAs of approximately 22 nucleotides 
in length. Numerous cellular processes are affected by 
miRNA, including differentiation, proliferation, cell-
cycle control, apoptosis, migration and invasion [4]. miR-
NAs exert their regulatory effects by binding to partially 
complementary sequences in the 3′-untranslated region 
(3′UTR) of target mRNAs, reducing the stability and/or 
translation efficiency of target mRNAs in a sequence-
specific manner. Accumulating evidence suggests that 
miRNAs are significant molecules in diverse cancers, 
including prostate cancer, by regulating the expres-
sion of various oncogenes and tumor suppressors [5, 6]. 
Large scale miRNA expression analyses indicated a com-
mon deregulation of miRNAs in tumors compared to 
their benign counterparts. For example, in the prostate 
cancer miRNA signature analysis carried out by Porkka 
et al. [7], expression profiling of 319 miRNAs in 6 pros-
tate cancer cell lines, 9 prostate cancer xenografts sam-
ples, and 13 clinical prostate tissue samples were used 
to classify prostate tumors. Here, 37 miRNAs (miR-16, 
miR-23a, miR-23b, miR-143, miR-145, miR-195,miR-221, 
miR-222, miR-497 et al.) were found to be downregulated 
in hormone-refractory late-stage prostate carcinomas, 
whereas 14 miRNAs were upregulated in hormonere-
fractory carcinomas. Schaefer et al. [8] validated that ten 
microRNAs (hsa-miR-16, hsa-miR-31, hsa-miR-125b, 
hsa-miR-145, hsa-miR-149, hsa-miR-181b, hsa-miR-184, 
hsa-miR-205, hsa-miR-221, hsa-miR-222) were down-
regulated and five miRNAs (hsa-miR-96, hsa-miR-182, 
hsa-miR-182, hsa-miR-183, hsa-375) were upregulated 
in prostate cancer. Meanwhile, several miRNAs were also 
shown to be deregulated and functionally relevant across 
different cancer diseases: down-regulation of miR-125a 
and miR-125b in breast cancer [9], the let-7 miRNAs in 
lung cancer [10], and miR-143 and miR-145 in different 
cancer types [11]. Besides, further investigations have 
assessed the diagnostic and prognostic value of miRNA 
profiling in prostate cancer. Of note, two promising miR-
NAs, miR-141 and miR-375, were suggested as diagnostic 
and prognostic marker across independent studies. Both 
miRNAs were found to be elevated in serum of men with 
metastatic castration-resistant prostate cancer compared 
to healthy individuals [12, 13]. To elucidate the role of the 
individual miRNAs in prostate cancer, genes and path-
ways which are regulated by the differentially expressed 
miRNAs should be studied. Thus, a set of targets of miR-
NAs have been identified in relevant studies. The restora-
tion of miR-205 has been shown to restrain cell viability 
via targeting MED1, miR-124 targets androgen receptor 
and inhibits proliferation of prostate cancer cells, miR 
-23b represses proto-oncogene Src kinase, miR-125a and 
miR-125b suppress the oncogenes ERBB2 and ERBB3 
[14–17]. Although the study of miRNAs is still challeng-
ing due to variable downstream regulators, the above evi-
dence gives us a promising outlook for the application of 
miRNAs for prostate cancer management.
Several recent studies have presented a global analysis 
of miR-195 expression and function in different human 
cancers. Our previous study showed that overexpression 
of miR-195 could induce G1-phase arrest by targeting 
the novel target CDK4 in bladder cancer cells [18]. It was 
reported that miR-195 could block the G(1)/S transition 
in hepatocellular carcinoma cells by repressing Rb-E2F 
signaling through targeting multiple molecules, includ-
ing cyclin D1, CDK6, and E2F3 [19]. miR-195 played a 
tumor-suppressor role in human glioblastoma cells by 
targeting E2F3 and CCND3 involved in cellular prolifera-
tion and invasion [20]. Besides, it also promoted colorec-
tal cancer cell apoptosis by repressing Bcl-2 [21]. In the 
current study, we aimed to determine the role of miR-195 
in determining the aggressiveness of prostate cancer cells 
and studied the correlated regulatory mechanism of miR-
195. We found that miR-195 expression was downregu-
lated in two prostate cancer cell lines, ectopic expression 
of miR-195 significantly suppressed cell migratory and 
invasive capacities of PC3 and DU145 cells through inhi-
bition of Fra-1. These findings indicated that miR-195 
could be a potential tumor suppressor by directly binding 
to Fra-1 in prostate cancer.
Methods
Cell lines and cell culture
The human prostate cancer cell lines PC3, Du145 and 
normal human prostate cells (RWPE-1) were obtained 
from the Shanghai Institute of Cell Biology (Shanghai, 
China), and were cultured in RPMI 1640 medium sup-
plemented with 10 % heat-inactivated fetal bovine serum 
and incubated at 37 °C in a humidified incubator with 5 % 
CO2.
miRNAs and transfection
miR-195 mimic(sense 5′-UAGCAGCACAGAAAUAU 
UGGC-3′) and the negative control(sense 5′-ACUACU 
GAGUGACAGUAGA-3′) were chemically synthesized 
by GenePharma (Shanghai, China). For convenience, 
miR-195 mimic and the negative control are termed miR-
195 and NC, respectively. The day before transfection, 
the cells were plated to 60–70  % confluency in growth 
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medium without antibiotics. The transfection was per-
formed using Lipofectamine 2000 Reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s 
instruction.
RNA extraction and real‑time quantitative PCR (qPCR)
Total RNA was extracted from cultured cells by using 
TRIzol reagent (Takara, Japan) and reverse transcribed 
into cDNA using a PrimeScript® RT reagent Kit (Takara, 
Japan), while microRNA was isolated with RNAiso for 
Small RNA (Takara, Japan). Before PCR reaction, miRNA 
was polyadenylated and reverse transcribed using a One 
Step PrimeScript® miRNA cDNA Synthesis Kit (Takara, 
Japan). The levels of mRNAs and miRNAs were meas-
ured by real-time quantitative PCR using an ABI 7500 
Real-Time PCR System (Applied Biosystems, Carlsbad, 
USA) with SYBR Premix Ex Taq II (TaKaRa, Japan). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and U6 small nuclear RNA were used as internal controls 
for detection. The relative expression level of miR-195 
and Fra-1 was calculated and quantified with the 2−ΔΔCt 
method after normalization. All the primer sequences 
(forward and reverse) are listed as follows:
(1) miR-195: GATAGCAGCACAGAAATATTGGC; (2) 
U6: TGCGGGTGCTCGCTTCGGCAGC; (3) GAPDH F: 
AAGGTGAAGGTCGGAGTCA and GAPDH R: GGA 
AGATGGTGATGGGATTT; (4) Fra-1 F: CAGCTCAT 
CGCAAGAGTAGCA and Fra-1 R: CAAAGCGAGGAG 
GGTTGGA.
Luciferase activity assay
We designed oligonucleotide pairs that contain the 
regions with or without a possible binding site from the 
3′ untranslated region (UTR) of Fra-1,then the desired 
sequences were annealed and ligated into the pmirGLO 
Dual-Luciferase miRNA Target Expression Vector (Pro-
mega, USA) between the SacI and SalI sites according 
to the manufacturer’s protocol. Both insertions were 
verified by sequencing. HEK293T cells were co-trans-
fected with 0.2 µg luciferase reporter vector comprising 
wildtype or mutant 3′-UTR and 50 nM miR-195 or miR-
NC, using Lipofectamine 2000 (Invitrogen) in the 24-well 
plates. The cells were harvested 48  h post-transfection, 
and the luciferase activity was measured by Dual-Lucif-
erase Reporter Assay System (Promega, USA). Luciferase 
activities were shown as firefly luciferase/renilla lucif-
erase ratio.
Cell proliferation assay
Cells were seeded in 96-well plate at a density of 4 × 103/
well. After an overnight incubation, the cells were trans-
fected with the RNA duplexes (miR-195, siFra-1or 
control) for 2–3  days. Subsequently, the medium was 
removed, cell counting solution (WST-8, Dojindo Labo-
ratories, Japan) was added to each well, and the cells 
incubated for an additional 1  h. The absorbance of the 
solution was measured spectrophotometrically at 450 nm 
with a MRX II absorbance reader (Dynex Technologies, 
USA).
Cell migration and invasion assay
In vitro, cell migration and invasion assays were per-
formed using transwell chambers (pore size of 8  µm; 
Costar, Corning, Switzerland), which bottom was coated 
with 1 mg/ml BD Matrigel Matrix (BD Biosciences, USA) 
for invasion assays specifically. The inserts were placed 
in the 24-well culture plates. PC3 and Du145 cells were 
transfected as mentioned above. Post-transfected cells 
(48  h) were trypsinized and resuspended in serum-
free RPMI 1640 medium, and 200 µl of the cell suspen-
sion (8–10 × 104 cells) was added to the upper chamber 
of uncoated (for migration assays) or Matrigel coated 
(for invasion assays) membranes, meanwhile 600  µl of 
medium containing 10 % fetal bovine serum was added to 
the lower chamber as chemoattractant. After 24 or 48 h 
of incubation at 37  °C in a 5  % CO2 humidified atmos-
phere, the cells that had not migrated through the pores 
were manually removed from the upper face of the filters 
using cotton swabs, and Cells adherent to the bottom 
surface of the inserts were fixed in cold 100 % methanol 
for 10 min and then stained with 0.01 % crystal violet for 
2 min. Finally the filters were washed thoroughly in water 
and images were taken under a microscope (Olympus, 
Japan) with appropriate magnification. These experi-
ments were done in triplicate and performed a minimum 
of three times.
Wound healing assay
Approximately 1 ×  105 PC3 or Du145 cells were plated 
in each well of a 6-well plate. After overnight incuba-
tion, cells were respectively transfected with 50 nM miR-
195 or miR-NC. When cell confluence reached about 
90–100  % after transfection, wounds were created in 
confluent cells using a 200 µl pipette tip. The cells were 
rinsed several times with media to remove any free-float-
ing cells and debris, and placed back in growth medium. 
Wound healing was observed at different time points(0, 
24, 48 h)within the scrape line, and representative scrape 
lines for each cell type were photographed using phase-
contrast microscope (Olympus, Japan). The results were 
quantified by Image J software.
Western blotting analysis
In brief, the transfected cells were harvested, washed and 
lysed with RIPA buffer. The protein concentration was 
measured using the bicinchoninic acid protein assay kit 
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(Pierce Biotechnology, Rockford, IL, USA). Equivalent quan-
tities (30–50 µg) of protein were separated by 12 % sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene fluoride micropo-
rous (PVDF) membranes (Millipore, Bedford, MA, USA). 
The membranes were blocked with 5 % non-fat milk in Tris-
buffered saline for 2 h and incubated overnight at 4 °C with 
primary antibodies against Fra-1, MMP9, c-Met, GAPDH, 
HMGA1, vimentin antibody (Epitomics, Burlingame, USA), 
MMP1 (Santa Cruz) at dilutions specified by the manufac-
turer. The membranes were washed 3 times in TBS-Tween 
and incubated with the corresponding horseradish peroxi-
dase (HRP)-conjugated secondary antibody at a 1:5000 dilu-
tion for 1 h. Bound secondary antibody was detected using 
an enhanced chemiluminescence (ECL) system (Pierce Bio-
technology Inc, Rockford, USA). Western-blot results were 
analyzed quantitatively by Image J Software.
Fra‑1 suppression by siRNA
Small silencing RNA (siRNA) interfering Fra-1 (siFra-1) 
(sense 5′-CACCAUGAGUGGCAGUCAGdTdT-3′ and 
antisense 5′-CUGACUGCCACUCAUGGUGdTdT-3′) 
and the negative control siRNA (siNC) were chemically 
synthesized (GenePharma, Shanghai, China). The target 
cells were transfected with 50 nM siRNA or negative con-
trol RNA and the vitro cell migration and invasion assays 
were performed 48 h after the siRNA transfection. Addi-
tionally, total RNAs and protein were prepared for real-
time reverse transcription–polymerase chain reaction 
(RT–PCR) and western blotting analysis.
miR‑195 inhibitor experiments
To further investigate the function of miR-195, the 
antisense inhibitor (miR-195 inhibitor) experiments 
were performed to see whether the reverse effects to 
over-expression could be demonstrated. 2′-O-methyl 
modified miR-195 inhibitor (named as miR-195-Inhi, 
5′-GCCAAUAUUUCUGUGCUGCUA-3′) and NC 
inhibitor (named as Inhi-NC, 5′-CAGUACUUUUGU-
GUAGUACAA-3′) were used. The cells were co-trans-
fected with either miR-195 mimics or NC oligos with 
miR-195 inhibitor or NC inhibitor. After 48  h of trans-
fection, transwell assay was assessed. In order to iden-
tify miR-195 targeting Fra-1 accurately, we established 
two groups: siFRA-1  +  miR-195-Inhi, siFRA-1  +  Inhi 
-NC, and then the cell migration and invasion should be 
assessed. Besides, expression level of miR-195 was calcu-
lated by quantitative PCR. In addition, the Fra-1 expres-
sion was determined by western blotting.
Fra‑1 rescue experiments
The Fra-1 over-expression plasmid was obtained by 
inserting the human Fra-1 complementary DNA lacking 
the 3′-UTR into the pIRES2-eGFP (Clontech, USA, the 
over-expression clone of Fra-1 would be termed as pFra-
1) between the HindIII and XhoI sites. The vector was 
verified by sequencing before application. After prepara-
tion, miR-195 or miR-NC was co-transfected with pFra-1 
or the empty control vector (pNull). The cells were col-
lected and analyzed for migration and invasion as 
described above. The efficiency of Fra-1 over-expression 
was verified by western blotting.
Tissue microarrays
A commercial human prostate cancer tissue microarray 
bearing 29 pairs of prostate cancer and corresponding 
non-tumor tissues was purchased from Shanghai Outdo 
Biotech (product ID: OD-CT-UrPrt03) for Fra-1 expres-
sion pattern analysis. For immunohistochemical (IHC) 
staining, tissue sections were deparaffinized in xylene, 
hydrated with graded ethanol and quenched for endog-
enous peroxidase activity in 0.3  % hydrogen peroxide. 
Microwave heating was performed in sodium citrate 
solution (pH 6.0) for epitope retrieval, and goat serum 
was used for blocking. The slides were incubated with 
anti-Fra-1 primary antibody (Epitomics, Burlingame, 
USA) at 4 °C for 16 h and incubated with a HRP-conju-
gated secondary antibody at room temperature for 1  h. 
DAB was applied for color development, dark brown was 
considered positive staining. Hematoxylin was applied 
for counterstain. The images were obtained under a 
microscope (Olympus, Japan). The Strength of positiv-
ity was semi-quantified by comprehensively considering 
staining intensity and the proportion of positive cells.
Statistics
The data were expressed as the mean  ±  SD of three 
independent experiments. The statistical analysis were 
performed using SPSS 17.0 statistical software (SPSS, 
Chicago, IL, USA). Student’s t test and Two-way ANOVA 
were used to compare intergroup differences. A p value 
of <0.05 was considered to be statistically significant.
Results
The expression of miR‑195 was frequently downregulated 
in human prostate cancer
Previous studies demonstrated that miR-195 was 
downregulated in prostate cancer [7], in this study, we 
examined the expression levels of miR-195 in one immor-
talized prostatic epithelial cell line, RWPE-1, and two 
prostate cancer cell lines, PC3 and DU145, by miR-quan-
titative RT-PCR analysis. As shown in Fig.  1a, prostate 
cancer cell lines had lower endogenous miR-195 levels 
when compared with the non-tumor epithelial cell line. 
Thus, we speculated that miR-195 might be a putative 
tumor suppressor in prostate cancer. In order to identify 
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downstream targets of miR-195, bioinformatics analysis 
was carried out using online algorithms including Tar-
getScan (http://targetscan.org/) and PicTar (http://pictar.
mdc-berlin.de/cgi-bin/new_PicTar_vertebrate.cgi). We 
found that Fra-1 was a possible target of miR-195. Then 
the mRNA levels of Fra-1 in above three prostate cell 
lines were determined by quantitative PCR. An increased 
expression pattern of Fra-1 was observed in DU145 and 
PC3 cells compared with RWPE-1 cells (Fig. 1b, d). Fur-
thermore, the expression levels of Fra-1 protein were 
markedly higher in cancerous tissues comparing with 
their non-cancerous counterparts in tissue microarray 
by IHC staining (Fig.  1e).Typical immunohistochemical 
findings of Fra-1 are shown in Fig.  1c. Detailed clinical 
information about this microarray was provided in Addi-
tional file  1: Table S1. These results indicated that high 
miR-195 level in normal prostatic epithelium cells might 
play a tumor-suppressive role through negatively regulat-
ing Fra-1 expression suggesting that downregulation of 
miR-195 might be involved in the prostate tumorigenesis 
and progression. Subsequently, we focused on the corre-
lation between Fra-1 protein and miR-195.
Introduction of miR‑195 inhibited migration and invasion 
of prostate cancer cells in vitro
To elucidate that whether miR-195 could function as a 
tumor suppressor, the effects of miR-195 over-expression 
was evaluated in  vitro. First, we performed cell viability 
Fig. 1 Quantitative analysis of miR-195 and Fra-1 in prostate cancer cell lines, IHC staining of Fra-1 expression pattern in tissue microarray. a The 
miR-195 levels in prostate cancer cell lines DU145 and PC3 were determined and compared with non-tumor prostate cell line RWPE-1. The real-time 
PCR analysis were normalized with U6 snRNA. b An increased expression pattern of Fra-1 in mRNA level was observed in DU145 and PC3 cells 
compared with RWPE-1 cells. c There were 29 pairs of tissue in tissue microarray, and three pairs of tissue were excluded from further semiquantita-
tive analysis, since the corresponding tissue was lost during the staining process. IHC staining of Fra-1 in array and representative pair of dots was 
presented. d An increased protein expression of Fra-1 in DU145 and PC3 cells compared with RWPE-1. e Fra-1 showed in stronger positivity in 20 
out of 29 cancer tissues (cancer) compared with the paired non-tumor tissues (NT) (P < 0.05)
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assay to investigate whether miR-195 has a biological func-
tion in proliferation of cancer cells, miR-195 mimics and 
negative control mimics at a concentration of 50 nM were 
separately transfected into both DU145 and PC3 cells. As 
shown in Fig.  2a, the ectopic expression of miR-195 was 
confirmed by qRT-PCR, and no significant difference was 
observed between NC group and miR-195 treated group, 
miR-195 did not significantly affect cell viability (Fig. 2b). 
However, forced expression of miR-195 in both cells led to 
retarded wound closing compared to NC groups (Fig. 2c, 
d) with cell wound healing assay. To further confirm the 
above findings, we decided to perform cell migration and 
invasion assays by using transwell chambers within 48  h 
after miRNA transfection. Transwell assay showed that the 
motility were significantly reduced in the miR-195 overex-
pressing PC3 and DU145 cells as compared with the nega-
tive control (Fig. 3a, c). Moreover, RWPE-1 was chosen to 
be an additional control and transfected by miR-195 and 
NC as mentioned above, the transwell assays were per-
formed subsequently. The data was shown in additional 
file 2: Figure S1, which provide evidence to conclude that 
miR-195 indeed suppresses cell motility. Taken together, 
these results revealed that miR-195 negatively modulate 
prostate cancer cells migration and invasion.
miR‑195 inhibited Fra‑1 expression
To verify that miR-195 act as a Fra-1 suppressor, PC-3 
and DU145 cells were respectively transfected with 50 nM 
miR-195 and NC. Western blotting showed that at 72  h 
post-transfection, the overexpressions of miR-195 contrib-
uted to both significant decreases in Fra-1 protein levels in 
above two cell lines (Fig. 3e). On the other hand, qRT-PCR 
analysis demonstrated that Fra-1 mRNA levels had notable 
changes (Fig. 3b), suggesting that microRNA may suppress 
target gene expression through binding to its 3′-UTR.
Fra‑1 is a novel direct target of miR‑195
As previously described, two algorithm programs were 
used to predict miRNAs targeting the 3′-UTR of Fra-1. As 
shown in Fig. 3f, Fra-1 mRNA has one potential compli-
mentary miR-195 binding site within its 3′-UTR region. 
We next investigated whether Fra-1 was a direct functional 
target of miR-195. The 3′-UTR of Fra-1 was cloned into 
down-stream of firefly luciferase coding region of pmir-
GLO Dual-Luciferase miRNA Target Expression Vector. 
Additional vector with mutated putative binding sites was 
also constructed. Then HEK293T cells were co-transfected 
with either miR-195 or NC and reporter vectors contain-
ing wildtype (Wt) or mutant (Mut) 3′-UTR. The level of 
relative luciferase activity in the case of co-transfection 
with Wt 3′-UTR-reporter and miR-195 mimics was sig-
nificantly lower than that co-transfected with NC. On 
the contrary, the level of luciferase activity in the reporter 
bearing 3′-UTR with mutated binding sites was unaffected 
by a simultaneous transfection with miR-195. These find-
ings indicated that miR-195 inhibited Fra-1 expression 
through direct binding of 3′-UTR of its transcript. As illus-
trated in Fig.  3d, expression of motility-related markers, 
including c-Met, MMP1, MMP9, Vimentin and HMGA1 
were compared by western blot between NC and miR-195 
groups. The protein levels of these genes were significantly 
decreased in prostate cancer cells transfected with miR-
195, except for vimentin and HMGA1.
Decreased Fra‑1 expression reduced the migration 
and invasion capability of prostate cancer cells
As a novel target of miR-195, Fra-1 was reported to regu-
late cell motility and invasion in various malignant epithe-
lial cells. To determine whether these cell characteristics 
are affected by Fra-1 in prostate cancer cells, we knocked 
down Fra-1 with siRNA in PC3 and DU145 cells. The Fra-1 
mRNA level was analyzed using RT-PCR at 48  h after 
transfection, which was obviously decreased in siFra-1 
transfected prostate cancer cells (Fig.  4a). Knockdown of 
Fra-1 protein expression was also confirmed by Western 
analysis (Fig.  4b). With the efficient knockdown of Fra-1, 
we performed cell viability assay, there was no significant 
difference in both cell lines between siFra-1 groups and NC 
groups (Fig. 4c). Wound healing assay and transwell assay 
showed that the migration and invasion of siFra-1-trans-
fected cells were significantly reduced as compared with 
the control cells (Figs. 4d, 5a, b). The knock-down of Fra-1 
through RNAi approach yielded the anticipated cell physi-
ological function, which phenocopied the effect of miR-
195 over-expression. Furthermore, Fra-1 had been shown 
to regulate the expression of the MMP family members in 
many cancer cells [22, 23]. It also affected other regulators 
of cell motility, including c-Met, vimentin and HMGA1 
in malignant cells [24, 25]. As exhibited in 5C, the protein 
expressions of c-Met, MMP1, MMP9 were decreased in 
siRNA transfected prostate cancer cells.
Inhibition of miR‑195 partially reverses the overexpression 
of miR‑195 induced effects
To better verify the function of miR-195, the antisense 
inhibitor experiments were performed to see whether the 
reverse effects could be observed. As a result, co-trans-
fection of miR-195-Inhi was applied to attenuate the miR-
195 expression promotion in the level of mRNA (Fig. 6a). 
The Fra-1 expression inhibition by miR-195 in the level of 
protein could be reversed in both cells (Fig. 6b). Although 
PC3 and DU145 are both castration resistant prostate 
cancer cells, they have different genetic backgrounds and 
biological properties, which may respond to inhibitor 
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oligos at different levels. Furthermore, miR-195-Inhi 
could partially abrogate the effect of miR-195 on cells 
migration and invasion ability (Fig. 6c). Moreover, the cell 
migration and invasion in cell lines with silence of Fra-1 
could be partially restored when the miR-195 level was 
downregulated (Fig.  7a). Thus, we confirmed that miR-
195-Inhi could reverse the effects to over-expression of 
miR-195.
Forced Fra‑1 expression partially rescued the migration 
and invasion capability of miR‑195‑transfected prostate 
cancer cells
To further investigate whether the effects of miR-195 on 
cell motility are mediated by Fra-1, we next carried out 
cell migration and invasion assays in DU145 cells that 
were co-transfected with miR-195 and the pFra-1 plasmid, 
which lacked the 3′-UTR of Fra-1 and therefore cannot be 
Fig. 2 Forced expression of miR-195 suppressed cell motility in wound healing assay without significantly affecting cell viability. a The ectopic 
expression of miR-195 was confirmed by qRT-PCR. Three independent experiments were performed in each group. b Cell viability assay. Overex-
pression of miR-195 had no apparent effect on prostate cancer cell viability (cell viability of 0 nM was regarded as 1.0, n = 3). c, d DU145 and PC3 
cells were transfected with NC, miR-195 mimics at a concentration of 50 nM and were performed wound healing assays with a 24–48 h recovery 
period, the wound area was measured by Image J software (*P < 0.05)
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Fig. 3 Transfection with miR-195 impaired the motility of prostate cancer cells and Fra-1 is a direct target of miR-195. a, c DU145 and PC3 cells 
were transfected with NC, miR-195 mimics and cell migration and invasion were assessed after 48 h incubation by transwell assay. Representative 
micrographs of the cell migration and invasion assay (left) and quantification (right) from three independent experiments were presented at ×100 
(*P < 0.05). b, e The Fra-1 expression level was significantly reduced following treatment with miR-195 mimics by RT-PCR and western blot in DU145 
and PC3 cells. d Representative western blotting results of motility-related proteins in miR-195-transfected DU145 and PC3 cells, band intensity 
quantification was made by Image J software, while GAPDH used as a loading control (n = 3; *P < 0.05). f A schematic of the computational 
predicted seed region in the 3′-UTR of Fra-1 (conserved in human, rhesus, dog, rat, mouse) was shown, while mutations on the “seed” sequences 
were designed as below. HEK293T cells were co-transfected with 50 nM of either miR-195 or NC and 200 ng pmirGLO Dual-Luciferase miRNA Target 
Expression Vector comprising Wt or Mut 3′-UTR of Fra-1. miR-195 significantly suppressed the firefly luciferase activity of construct with Wt 3′-UTR of 
Fra-1 (*P < 0.05)
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Fig. 4 Silence of Fra-1 impaired cell motility in wound healing assay without significantly affecting cell viability. a The efficiency of siRNA was con-
firmed by real-time PCR. The relative Fra-1 mRNA levels were determined by RT-PCR in siRNA transfected cells (n = 3; *P < 0.05). b The knock-down 
of Fra-1 via RNAi technique reduced the expression of Fra-1 at protein level, while GAPDH used as a loading control (n = 3; *P < 0.05). c Transfection 
of siFra-1 had no apparent effect on prostate cancer cell viability, concentration of the reagent and time course of the cell proliferation (24, 48 and 
72 h after transfection) were provided. d Wound healing assays with siFra-1 in DU145 and PC3 cells were performed at 24 and 48 h, the wound area 
was measured by Image J software (*P < 0.05)
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Fig. 5 Knock-down of Fra-1 phenocopied the effect of miR-195. a, b siFra-1 yield an inhibitory effect on migration and invasion in both prostate 
cancer cell lines (×100), quantitative analysis were made from triplicate experiments (*P < 0.05). c Expression of motility-related markers were 
compared by western blot between NC and siFra-1 groups, band intensity quantification was calculated by Image J software, GAPDH was used as a 
loading control (*P < 0.05)
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inhibited by miR-195. The results showed that forced Fra-1 
expression increased the migratory and invasive capabilities 
of prostate cancer cells. More importantly, this restoration 
of Fra-1, partially, but significantly, rescued the migra-
tion and invasion capability of miR-195-transfected cells 
(Fig. 7b). Besides, the Fra-1, c-Met, MMP1, MMP9 protein 
Fig. 6 Inhibition of miR-195 partially reversed the over-expression of miR-195 induced effect. a Inhibitor of miR-195 suppressed the expression of 
miR-195. DU145 and PC3 cells were co-transfected with miR-195-Inhi (vs. Inhi-NC) and miR-195 (vs. NC). The expression of miR-195 was determined 
by real-time PCR, snRNA U6 served as an internal control (*P < 0.05). b The expression of Fra-1 was determined by western blot analysis after miR-
195 inhibitor treatment, western-blot results should be analyzed quantitatively (*P < 0.05). c The prostate cancer cells migration and invasion ability 
was restored after miR-195-Inhi transfection (×100) (*P < 0.05)
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Fig. 7 Forced expression of Fra-1 or miR-195-inhibitor partially rescued miR-195-dependent suppression of tumorous behavior. a DU145 and 
PC3 cells were co-transfected with either miR-195-inhibitor or Inhibitor-NC oligos with siFra-1. Transwell assays were conducted and quantified 
(*P < 0.05). b Forced expression of Fra-1 abrogated cell motility impairment by miR-195 (representative migration and invasion results at ×100 were 
shown). Quantitative analysis revealed a significant increase in cell migration and invasion after Fra-1 re-expression. c Western blot analysis was 
performed to confirm the re-expression of Fra-1 and other related proteins
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expressions confirmed by western blot analysis were con-
sistent with transwell assay (Fig. 7c). Taken together, these 
data suggested that the effects of miR-195 on cell migration 
and invasion were in part mediated by Fra-1.
Discussion
It is well known that invasion and metastasis are the most 
significant biological characteristics of malignant tumors 
and advanced metastatic PCa is currently incurable. How-
ever, it is the great challenge of current basic and clinical 
research to identify novel molecular targets that could 
improve the therapeutic strategies to combat this lethal 
cancer, the application and efficacy of these therapies are 
still limited. During the last decades, an increasing number 
of studies have demonstrated that deregulation of miRNAs 
was a common event in tumor tissues and miRNAs would 
be treated as ideal tumor biomarkers or therapeutic targets 
[26–29]. Previously a systematic review has summarized 
that the deregulated miRNAs are common in prostate 
cancer [30]. Although a series of relevant studies have cre-
ated signatures for prostate cancer, which will help further 
establish molecular diagnosis, prognosis and therapy using 
miRNAs, the function and mechanisms of specific miR-
NAs in prostate cancer are still poorly understood.
Recently, a number of studies have shown that the roles 
of miR-195 may be controversial in different types of can-
cers. miR-195 expression was reported to be elevated in 
chronic lymphocytic leukemia [31] and it was consid-
ered to be an oncomiR. However, in majority of cancers, 
miR-195 was suggested to function as a tumor suppres-
sor in cancer development and progression, which was 
consistent with its expression patterns in hepatocellular 
carcinoma [19], adrenocortical carcinoma [32, 33], colo-
rectal cancer [21], breast cancer [34], bladder cancer 
[35, 36] and squamous cell cancer of tongue [37]. More 
importantly, a miRNA signature study had also shown 
that miR-195 was down-regulated in prostate cancer 
[7]. Our previous work confirmed that miR-195 was fre-
quently down-regulated in bladder cancer. miR-195, as a 
tumor suppressor in bladder cancer cells, could induce 
G1-phase arrest by targeting the novel target CDK4. But 
the underlying mechanisms mediating miR-195 deregu-
lation in cancer development are still elusive, particularly 
in tumor metastasis, and whether the deregulation of 
miR-195 expression in cancer is mediated by epigenetic 
alterations remains to be further investigated. Therefore, 
the potential function of miR-195, such as suppressing 
cell migration and invasion in prostate cancer, triggers 
our initial interest.
In the current study, we revealed a decrease in expres-
sion of the newly identified tumor suppressive miR-195 
in two human prostate cancer cell lines PC3 and DU145 
compared with normal prostatic epithelial cells RWPE-1. 
Our quantification analysis yielded a similar expres-
sion pattern with former miRNA signature results. But 
whether the Fra-1 expression level inversely correlated 
with the miRNA expression profile in prostate cancer tis-
sue needs to be further investigated.
Furthermore, we validated the functional roles of 
miR-195 in prostate cancer cell lines by gain of function 
study. By transfecting cancer cells with miR-195 mim-
ics, we revealed that miR-195 was a potential metastasis 
suppressor for PCa as miR-195 expression significantly 
diminished the cell motility and invasion capability of 
PCa cells. A series of transwell experiments showed that 
the migration and invasion were significantly reduced in 
the selective miR-195 overexpressing PCa cells as com-
pared with the control ones. Meanwhile, the downregula-
tion of Fra-1 expression at both mRNA and protein levels 
was observed. Moreover, dual luciferase reporter assay 
confirmed that miR-195 could specifically inhibit Fra-1 
by binding to a critical region located on its 3′-UTR. 
These results suggest a targeted downregulation of Fra-1 
by miR-195 in prostate cancer, and miR-195 functions as 
an inhibitor of prostate cancer progression.
Fra-1 was frequently reported to be prominently asso-
ciated with tumor invasiveness, metastatic dissemina-
tion. It was validated to be overexpressed in various 
human malignancies, including breast cancer [38, 39], 
lung adenocarcinoma [23] and colon carcinoma cells 
[25]. Consistent with these observations, our study 
showed higher expression of Fra-1 in 20 of 29 (69  %) 
tumor tissues as compared with the adjacent normal 
tissues in a prostate cancer tissue microarray. Despite 
accumulating evidence pointing to promotive role of 
Fra-1 in metastasis, its interaction with miR-195 in cell 
migration and invasion has never been investigated, 
and its precise molecular mechanisms in the cellular 
malignant and invasive phenotypes are not fully under-
stood. Fra-1 was one of the transcription factor com-
plex activator protein-1 (AP-1) which played a central 
role in regulating gene transcription in several biologi-
cal processes, including cell proliferation, differentiation, 
transformation, inflammation, and pulmonary defense. 
AP-1 was constituted of a great variety of dimers com-
posed of members of Jun (c-Jun, Jun-B and Jun-D) and 
Fos (c-Fos, Fos-B, Fra-1 and Fra-2) proto-oncogenes. 
Overexpression of Fra-1 was a common mechanism of 
constitutive AP-1 activation in tumors and associated 
with AP-1-mediated transformation [40]. Yet, more and 
more data presented support that a shift of Fra-1 expres-
sion is an important step in carcinogenesis and/or pro-
gression. Besides, it had been demonstrated that Fra-1 
directly induced MMP-1 and MMP-9 promoter activi-
ties in breast cancer cells and stimulated MMP-2 and 
MMP-9 expression to enhance the motility and invasion 
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of lung cancer cells [23]. More interestingly, inhibition of 
Fra-1 by miR-34a led to downregulation of MMP-1 and 
MMP-9 in colon cancer cells, and eventually inhibited 
cell migration and invasion [41]. Matrix metalloprotein-
ases (MMPs), especially MMP1 and MMP9, are critical 
enzymes responsible for the degradation of the base-
ment membrane (BM) and extracellular matrix (ECM), 
thereby contributing to cancer invasion and metastasis. 
Previous studies have indicated that MMP1 and MMP9 
activity could be upregulated by c-Met [42]. Of note, in 
our study, MMP1, MMP9 and c-Met were also signifi-
cantly decreased in miR-195-transfected cells, although 
they were not direct targets of miR-195. In addition, we 
also observed that MMP1, MMP9 and c-Met expression 
could be downregulated in Fra-1-silenced cells. These 
results indicated that miR-195 might reduce cell migra-
tion and invasion partially through indirectly regulat-
ing MMP1, MMP9 and c-Met. The above-mentioned 
reports may help to explain the mechanisms and path-
ways of anti-Fra-1 methods on migration and invasion of 
cancer cells.
Here, we found that the specific Fra-1 knock-down with 
siRNAs phenocopied the migration and invasion inhibi-
tory effects of miR-195 over-expression, and forced Fra-1 
expression by transfecting certain constructed plasmids 
or miR-195 inhibitor experiments could partially rescued 
the migration and invasion capability of miR-195-trans-
fected cells, which further strengthened our findings that 
Fra-1 was an important mediator of miR-195-induced 
biological function.
Conclusion
In conclusion, we were able to illustrate for the first time 
that miR-195 can regulate prostate cancer cell migration 
and invasion through its direct target gene Fra-1 by tar-
geting it in a classical 3′-UTR binding fashion. Our find-
ings suggest that miR-195 may function as a potential 
biological molecule for preventing metastasis of prostate 
cancer, which may lead more new diagnostic and thera-
peutic approaches for prostate cancer, and provide new 
insights into the posttranscriptional regulation of Fra-1. 
Indeed, it is probable that other regulators of Fra-1 may 
also participate in prostate cancer development and our 
future studies should pay more attention to examining 
how Fra-1 is regulated in PCa or other human diseases.
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